Abstract
BACKGROUND: Ovarian clear cell cancer (OCCC) is a pathological type of ovarian cancer. OCCC responds poorly to platinum-based chemotherapy drugs and immunotherapy. Currently, there is a lack of targeted drugs for OCCC. It is very urgent to find new therapeutic targets for OCCC. METHODS: We used data from the eQTLGen consortium and deCODE, combined with large Genome-Wide Association Study (GWAS) cohort data, to perform drug target Mendelian randomization (MR) analysis. Colocalization analysis was used to identify target genes. Then, we analyzed single-cell sequencing data from the GEO database, combing with gene enrichment analysis to explore possible molecular mechanisms. Drug screening and molecular docking verified the medicinal value of the targets. RESULTS: Three genes were selected in the MR analysis. Colocalization supported two of them, PPP1R14A and PTGS2. Single-cell sequencing analysis showed that these genes were related to tumor immunity. Drug prediction and molecular docking showed that PTGS2 had druggable potential. CONCLUSIONS: This study identified two potential drug targets for OCCC. These drug targets may be relevant to tumor immunotherapy. However, further studies are necessary to confirm these findings and clarify the underlying mechanisms.